Virginia Elmiron Pigmentary Maculopathy injury lawyer
For years, patients trusted Elmiron (pentosan polysulfate sodium) to manage the pain of interstitial cystitis. But by 2026, the medical and legal communities have fully acknowledged a devastating truth: long-term use of this drug can cause irreversible retinal damage known as pigmentary maculopathy. We represent Virginia residents who took Elmiron and now face permanent vision loss, helping them pursue compensation from the manufacturer for failing to warn about this catastrophic side effect.
Our firm has dedicated resources to understanding the science behind Elmiron toxicity. The link between the drug and retinal degeneration was first reported in 2018, but evidence shows that Janssen Pharmaceuticals (a Johnson & Johnson subsidiary) had signals years earlier. Today, the FDA requires a warning label, but for thousands of patients who took the drug before those warnings, the damage is done. We are actively litigating claims in Virginia state courts and the federal multidistrict litigation (MDL) in the District of New Jersey.
The Elmiron MDL and Virginia's Role in the Litigation
The federal Elmiron litigation is centralized under MDL No. 2973 before Judge Brian R. Martinotti in New Jersey. Virginia plaintiffs are a significant part of this MDL, with dozens of cases filed from the Commonwealth. The first bellwether trials are scheduled for late 2026, and we are preparing to present evidence that Janssen knew about the risk of pigmentary maculopathy but concealed it from doctors and patients.
Virginia law adds specific urgency. Under Virginia’s statute of repose for product liability, plaintiffs generally have two years from the date they discovered—or reasonably should have discovered—their injury to file a claim. For many Elmiron patients, that clock started ticking only when an ophthalmologist diagnosed them with pigmentary maculopathy. We help clients document the date of diagnosis and the duration of Elmiron use to ensure their case is timely filed.
| Key Factor | Details for Virginia Elmiron Cases |
|---|---|
| Statute of Limitations | 2 years from discovery of injury (diagnosis of maculopathy) |
| MDL Venue | District of New Jersey (MDL No. 2973) |
| First Bellwether Trial | Scheduled Q3 2026 |
| Typical Exposure Duration | 3+ years of daily Elmiron use before retinal damage appears |
| Compensable Damages | Medical monitoring, vision aids, lost income, pain and suffering |
What Virginia Patients Need to Know About Retinal Toxicity
Elmiron-induced pigmentary maculopathy is a progressive condition. Early symptoms include difficulty reading, delayed dark adaptation, and central vision distortion. By the time a patient notices changes, significant retinal damage has often already occurred. We work with leading retinal specialists who can perform optical coherence tomography (OCT) and fundus autofluorescence imaging to document the characteristic pattern of toxicity.
The science has evolved dramatically since 2020. A 2025 meta-analysis published in Ophthalmology Retina confirmed that approximately 25% of patients taking Elmiron for more than five years develop some degree of maculopathy. That is one in four patients—a risk rate that Janssen never disclosed. We believe the company prioritized profits over patient safety, and we are holding them accountable.
“The failure to warn about Elmiron’s retinal toxicity represents one of the most significant undisclosed drug safety issues of the last decade. Patients deserve compensation, and the manufacturer must be held responsible.” — Read the full case background at elabexperts.com and review the archived MDL documents at our archived case page.
Building Your Virginia Elmiron Case: Evidence and Next Steps
To pursue a claim, we need to establish three core elements: (1) you took Elmiron for interstitial cystitis, (2) you have been diagnosed with pigmentary maculopathy, and (3) the drug was a substantial factor in causing your condition. We gather medical records spanning your entire period of Elmiron use, pharmacy records, and ophthalmology reports. In Virginia, we also look for evidence that your prescribing physician was never warned about the retinal risk.
Here is what we recommend for Virginia residents who took Elmiron:
- Get a comprehensive eye exam with a retinal specialist familiar with drug-induced maculopathy. Ask for OCT imaging and a visual field test.
- Gather your prescription history from every pharmacy that filled Elmiron for you. We need dates, dosages, and prescriber names.
- Document any vision changes in a journal, including when you first noticed problems reading, driving at night, or adjusting to dim light.
- Do not delay. Virginia’s two-year clock is unforgiving. Contact us as soon as you have a confirmed diagnosis.
We are currently accepting new Virginia Elmiron cases on a contingency basis—you pay nothing unless we recover compensation for you. The 2026 bellwether trials will set important precedents, and we are committed to ensuring that Virginia patients have a seat at the table. Your vision is irreplaceable. Let us fight for the justice you deserve.